Invitae (NYSE:NVTA) stock is on the rise Monday despite a lack of news from the medical genetics company this morning.
There haven’t been any new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the shares of NVTA stock are up today. On that same note, no analysts are offering new coverage that would cause today’s rally.
Even so, shares of NVTA stock are seeing incredibly strong trading on Monday. With that comes some 6 million shares of the company’s stock changing hands. That’s a strong start to the day, as it’s already more than half of the company’s daily average trading volume of about 10.2 million shares.
What’s Behind the NVTA Stock Movement Today?
While it’s not clear why exactly investors are taking an interest in NVTA stock, it could be retail and day traders taking notice of its low price. At just 61 cents per share when markets closed on Friday, the low price of NVTA makes it easy for investors to buy up large stakes of the company’s shares.
Investors will also note that NVTA is currently trying to boost the price of its shares. This comes after the company received a non-compliance warning from the New York Stock Exchange in September.
NVTA stock is up 27.9% as of Monday morning. The stock was down 67.1% year-to-date as of Fridya’s close.
Investors seeking out even more of the most recent stock market stories today are in the right place!
InvestorPlace has traders covered with all of the hottest stock market coverage they need to know about on Monday. Among that is what has shares of Aerwins Technologies (NASDAQ:AWIN) stock rising, the biggest pre-market stock movers this morning and more. All of that news is available at the following links!
More Stock Market News for Monday
- Why Is Aerwins Technologies (AWIN) Stock Up 112% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
- BIRK Stock Alert: Will a Government Shutdown Cancel the Birkenstock IPO?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
